Cargando…

Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications

OBJECTIVE: The long-term effects of enzyme-replacement therapy (ERT) in Fabry disease are unknown. Thus, the aim of this study was to determine whether ERT in patients with advanced Fabry disease affects progression towards ‘hard’ clinical end-points in comparison with the natural course of the dise...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weidemann, F, Niemann, M, Störk, S, Breunig, F, Beer, M, Sommer, C, Herrmann, S, Ertl, G, Wanner, C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2013
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282332/ https://www.ncbi.nlm.nih.gov/pubmed/23586858 http://dx.doi.org/10.1111/joim.12077

Ejemplares similares

Association and diagnostic utility of diastolic dysfunction and myocardial fibrosis in patients with Fabry disease
por: Liu, Dan, et al.
Publicado: (2018)

Left Ventricular Geometry and Blood Pressure as Predictors of Adverse Progression of Fabry Cardiomyopathy
por: Krämer, Johannes, et al.
Publicado: (2015)

Kidney function as an underestimated factor for reduced health related quality of life in patients with Fabry disease
por: Wagner, Martin, et al.
Publicado: (2014)

High‐Sensitivity Troponin: A Clinical Blood Biomarker for Staging Cardiomyopathy in Fabry Disease
por: Seydelmann, Nora, et al.
Publicado: (2016)

Potential role of vitamin D deficiency on Fabry cardiomyopathy
por: Drechsler, Christiane, et al.
Publicado: (2013)

Skin Globotriaosylceramide 3 Load Is Increased in Men with Advanced Fabry Disease
por: Üçeyler, Nurcan, et al.
Publicado: (2016)

Chaperone Therapy in Fabry Disease
por: Weidemann, Frank, et al.
Publicado: (2022)

Diagnosis and Screening of Patients with Fabry Disease
por: Vardarli, Irfan, et al.
Publicado: (2020)

Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease
por: Moore, David F, et al.
Publicado: (2002)

Increased Arterial Diameters in the Posterior Cerebral Circulation in Men with Fabry Disease
por: Üçeyler, Nurcan, et al.
Publicado: (2014)

Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
por: Biegstraaten, Marieke, et al.
Publicado: (2015)

Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease
por: Fervenza, Fernando C, et al.
Publicado: (2008)

Fabry disease in children and the effects of enzyme replacement treatment
por: Pintos-Morell, Guillem, et al.
Publicado: (2009)

Cost-effectiveness of enzyme replacement therapy for Fabry disease
por: Rombach, Saskia M, et al.
Publicado: (2013)

A Distinct Urinary Biomarker Pattern Characteristic of Female Fabry Patients That Mirrors Response to Enzyme Replacement Therapy
por: Kistler, Andreas D., et al.
Publicado: (2011)

Myocardial lipid content in Fabry disease: a combined (1)H-MR spectroscopy and MR imaging study at 3 Tesla
por: Petritsch, B., et al.
Publicado: (2016)

Long-Term Effect of Enzyme Replacement Therapy with Fabry Disease
por: Komori, Manabu, et al.
Publicado: (2013)

Value of the CHA(2)DS(2)-VASc score and Fabry-specific score for predicting new-onset or recurrent stroke/TIA in Fabry disease patients without atrial fibrillation
por: Liu, Dan, et al.
Publicado: (2018)

Impaired small fiber conduction in patients with Fabry disease: a neurophysiological case–control study
por: Üçeyler, Nurcan, et al.
Publicado: (2013)

Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease
por: Lenders, Malte, et al.
Publicado: (2016)

Recurrent Cerebrovascular Complications under Enzyme Replacement Therapy in a Patient with Fabry Disease on Peritoneal Dialysis
por: Muto, Reiko, et al.
Publicado: (2022)

Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factors
por: Arends, Maarten, et al.
Publicado: (2017)

Enzyme replacement therapy for Fabry disease: A systematic review and meta-analysis
por: Alegra, Taciane, et al.
Publicado: (2012)

Enzyme replacement therapy for Fabry disease: some answers but more questions
por: Alfadhel, Majid, et al.
Publicado: (2011)

Enzyme replacement therapy and white matter hyperintensity progression in Fabry disease
por: Stefaniak, James D., et al.
Publicado: (2018)

Development of Lanzyme as the Potential Enzyme Replacement Therapy Drug for Fabry Disease
por: Deng, Mulan, et al.
Publicado: (2022)

Clinical features and enzyme replacement therapy in 10 children with Fabry disease
por: Li, Qian, et al.
Publicado: (2023)

Organ manifestations and long-term outcome of Fabry disease in patients with the GLA haplotype D313Y
por: Oder, Daniel, et al.
Publicado: (2016)

Fibrosis: a key feature of Fabry disease with potential therapeutic implications
por: Weidemann, Frank, et al.
Publicado: (2013)

Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis
por: Beck, Michael, et al.
Publicado: (2015)

Gender Differences in the Application of Spanish Criteria for Initiation of Enzyme Replacement Therapy for Fabry Disease in the Fabry Outcome Survey
por: Barba-Romero, Miguel-Ángel, et al.
Publicado: (2016)

Fabry nephropathy before and after enzyme replacement therapy: important role of renal biopsy in patients with Fabry disease
por: Kim, Il Young, et al.
Publicado: (2021)

Short-Term Efficacy of Enzyme Replacement Therapy in Korean Patients with Fabry Disease
por: Choi, Jin-Ho, et al.
Publicado: (2008)

Fabry disease: characterisation of the plasma proteome pre- and post-enzyme replacement therapy
por: Heo, Sun Hee, et al.
Publicado: (2017)

Genetic variants associated with Fabry disease progression despite enzyme replacement therapy
por: Scionti, Francesca, et al.
Publicado: (2017)

Effectiveness of enzyme replacement therapy in Fabry disease: Long term experience in Argentina
por: Cabrera, Gustavo, et al.
Publicado: (2017)

Variable clinical features of patients with Fabry disease and outcome of enzyme replacement therapy
por: Dutra-Clarke, Marina, et al.
Publicado: (2020)

Enzyme Replacement Therapy for FABRY Disease: Possible Strategies to Improve Its Efficacy
por: Iacobucci, Ilaria, et al.
Publicado: (2023)

X‐chromosomal inactivation patterns in women with Fabry disease
por: Wagenhäuser, Laura, et al.
Publicado: (2022)

Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease
por: Germain, Dominique P, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_2ori99df2c18mb8a5vciiel87v